IMPACT: Integrative Migraine Pain Alleviation Through Chiropractic Therapy

Sponsor
Harvard University Faculty of Medicine (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03177616
Collaborator
Brigham and Women's Hospital (Other), Palmer Center for Chiropractic Research (PCCR) (Other)
61
1
2
62.2
1

Study Details

Study Description

Brief Summary

This pilot study evaluates the addition of chiropractic treatment to conventional neurological care in the treatment of migraine headaches in adult women. Half of the participants will receive 10 chiropractic treatments in addition to their usual care over a 14 week period, while the other half will continue their usual medical care alone, as prescribed by their physician during that time period.

Condition or Disease Intervention/Treatment Phase
  • Other: Chiropractic Treatment
N/A

Detailed Description

Chiropractic care is a commonly used therapeutic intervention for the treatment of pain disorders, and some smaller studies have shown that it might be helpful for migraines. This pilot study will use a comprehensive model of chiropractic treatment which can include soft tissue mobilization, spinal manipulation, and postural and spinal stabilization and correctional exercises.

Specific Aims:

Aim #1 - Determine the feasibility of conducting a randomized control trial (RCT) of chiropractic care in adult women with migraine.

Aim #2 - To provide preliminary data on the safety and effectiveness of chiropractic care on migraine frequency, severity, duration, and medication use in adult women with migraine.

Aim #3 - To provide preliminary estimates of the effects of chiropractic on disability, health-related quality of life, and psychosocial well-being.

Study Design

Study Type:
Interventional
Actual Enrollment :
61 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Integrative Migraine Pain Alleviation Through Chiropractic Therapy
Actual Study Start Date :
Jun 7, 2017
Actual Primary Completion Date :
Jul 12, 2019
Anticipated Study Completion Date :
Aug 12, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Usual Care

Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.

Experimental: Chiropractic Treatment + Usual Care

Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.

Other: Chiropractic Treatment
The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows: posture correction/spinal stabilization exercises soft tissue relaxation techniques spinal manipulation (i.e. chiropractic adjustment)/mobilization breathing and relaxing techniques stretches, self-care ergonomic modifications bracing and supports

Outcome Measures

Primary Outcome Measures

  1. Change from baseline to the last four weeks of the intervention period in the number of migraine days. [From the baseline period to week 11 through week 14.]

    Participants will record number of migraines experienced in provided logs.

Secondary Outcome Measures

  1. Changes from baseline to the post-intervention period in the number of migraine days. [From the baseline period to week 15 through week 18.]

    Participants will record number of migraines experienced in provided logs for four weeks post-intervention.

  2. Number of responders [From the baseline period to week 11 through week 14 and to week 15 through week 18.]

    Participants who had a greater than 50% reduction in days with migraine per four week period.

  3. Change from baseline in the severity of migraine [From the baseline period to week 11 through week 14 and to week 15 through week 18.]

    Participants will record the severity of migraines on a scale of 1 to 10 in provided logs.

  4. Change from baseline in the duration of migraine [From the baseline period to week 11 through week 14 and to week 15 through week 18.]

    Participants will record the duration (hours) of migraines in provided logs.

  5. Change from baseline in the doses of acute migraine medications used [From the baseline period to week 11 through week 14 and to week 15 through week 18.]

    Participants will record the medications taken to treat/prevent their migraines in provided logs.

  6. Change from baseline in the scores on the Headache Impact Test (HIT-6) questionnaire [From baseline to 14 weeks and 18 weeks]

    The HIT-6 questionnaire evaluates headache related disability.

  7. Change from baseline in the scores on the Migraine Disability Assessment (MIDAS) [From baseline to 14 weeks and 18 weeks]

    The MIDAS is a 5-item questionnaire used to assess disability in migraine research.

  8. Change from baseline in the Migraine Specific Quality of Life Questionnaire version 2.1 (MSQv2.1) [From baseline to 14 weeks and 18 weeks]

    The MSQv2.1 measures how migraines affect a patient's daily life.

  9. Change from baseline in Numeric Rating Pain Scale (NRS) [From baseline to 14 weeks and 18 weeks]

    The NRS tool will be used to measure neck pain on a scale from 1 to 10.

  10. Change from baseline in 9-item Patient Health Questionnaire (PHQ-9) [From baseline to 14 weeks and 18 weeks]

    The PHQ-9 will be used to measure changes in mood.

  11. Change from baseline in the Generalized Anxiety Disorder 7-item (GAD-7) [From baseline to 14 weeks and 18 weeks]

    The GAD-7 will be used to measure changes in mood.

  12. Change from baseline in the Patient Reported Outcome Measures Information System -29 item questionnaire (PROMIS-29) [From baseline to 14 weeks and 18 weeks]

    The PROMIS-29 will be used to measure changes in mood.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of episodic migraine with or without aura (International Classification of Headache Disorders-II)

  • 4 to 13 days with migraines/month

  • More than one year of migraines

  • Agreeable to participate, commit to all study procedures, and to be randomized to either group

  • Fluent in English (required to complete self-report instruments)

Exclusion Criteria:
  • Currently, or having received chiropractic care in past 3 months for any condition

  • Any major systemic illness or unstable medical or psychiatric condition (e.g. Parkinson's disease, cancer) requiring immediate treatment or that could lead to difficulty complying with the protocol

  • History of stroke, carotid artery dissection, or vertebral artery dissection

  • Head or neck trauma within the past year

  • Diagnosis of medication overuse headache (International Classification of Headache Disorders-II)

  • Began use of new prophylactic medication for migraine headaches within the last 3 months

  • Currently taking prophylactic migraine medications other than propranolol and topiramate

  • Failure to complete baseline diary recordings of migraine activity and medication use during run-in phase

  • Currently, or having received Botox treatment for migraine

  • Current alcohol or substance abuse (self-reported)

  • Diagnosis of Ehlers-Danlos Syndrome

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Osher Clinical Center for Integrative Medicine at Brigham and Women's Hospital Boston Massachusetts United States 02467

Sponsors and Collaborators

  • Harvard University Faculty of Medicine
  • Brigham and Women's Hospital
  • Palmer Center for Chiropractic Research (PCCR)

Investigators

  • Principal Investigator: Peter Wayne, Ph.D., Harvard Medical School (HMS and HSDM)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peter Wayne, Associate Professor of Medicine, Harvard University Faculty of Medicine
ClinicalTrials.gov Identifier:
NCT03177616
Other Study ID Numbers:
  • 2017P000087
First Posted:
Jun 6, 2017
Last Update Posted:
Sep 13, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peter Wayne, Associate Professor of Medicine, Harvard University Faculty of Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 13, 2021